Canbi  Pharma  Tech  Cyfyngedig
1632051-40-1 zuranolone

1632051-40-1 zuranolone

Cas: 1632051-40-1
MF: C25H35N3O2
MW: 409.57
Einecs:
MDL Rhif:mfcd31619241

Anfon ymchwiliad
Disgrifiad

Eiddo

ffurfio solid crisialog
Berwi: 574.3 ± 3 0. 0 gradd
Dwysedd 1.32 ± 0. 1 g/cm3
hydoddedd dmf: 3 0 mg/ml; DMF: PBS (pH 7.2) (1: 2): 0.33 mg/ml; DMSO: 10 mg/ml
PKA15.17 ± 0. 60
 

 

Cais:

Mae Zuranolone yn steroid niwroactif sy'n gweithredu fel modulator allosterig positif o dderbynyddion asid aminobutyrig gama-a.
Ar Awst 4, 2023, cymeradwyodd FDA yr UD Zuranolone ar gyfer iselder postpartum, gan ei wneud y feddyginiaeth lafar gyntaf a ddefnyddir i drin iselder postpartum. Mae canlyniadau ymchwil glinigol yn dangos bod gan Zuranolone gyfradd rhyddhad sylweddol uwch o symptomau iselder mewn cleifion ag iselder postpartum difrifol na'r grŵp plasebo.
 

 

Cyfystyron:

Zuranolone

1632051-40-1

Sage -217

Zurzuvae

Sge -797

zuranolonum

1- [{2- [(3r, 5r, 8r, 9r, 10s, 13s, 14s, 17s) {-3- hydroxy -3, {13- dimethyl {{{{13 },8,8,8,8,8,8,8,8,8, 411, 411, 412 5,16, {17- tetradecahydro {-1 H-cyclopenta [a] phenanthren -17- yl] -2- oxoethyl] pyrazole -4- carboni

S-812217

Zuranolonesage -217

Sage217

3Beta-Methyl -21- (4- cyano -1 H-pyrazol -1 '-yl) -19- norpregnanolone

3alpha-hydroxy -3 beta-methyl -21- (4- cyano -1 H-pyrazol -1 '-yl) {}}} na} na} na}

1- (3Alpha-hydroxy {-3 beta-Methyl {-20- oxo -19- na -5 beta-pregnan -21- yl)}}}}}

1h-pyrazole -4- carbonitrile, 1- ((3alpha, 5beta) -3- hydroxy -3- methyl -20- oxo {}}}} norpregNan

Zurzuvae (tn)

Zuranolone [who-dd]

Zuranolone [USAN: Inn]

Biib125

Zuranolone (saets -217)

Zuranolone (Jan/Usan/Inn)

Biib -125

Sage 217

Schembl16189866

GTPL12858

 

Tagiau poblogaidd: 1632051-40-1 Zuranolone, China 1632051-40-1 Gwneuthurwyr Zuranolone, Cyflenwyr

Inquiry
goTop

(0/10)

clearall